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Abstract 
Background. Human papillomavirus (HPV) infection is the most
common sexually transmitted infection and high-risk HPV types are a
necessary cause for the development of cervical cancer. The present
study investigated the HPV-type specific prevalence in 650 women,
aged 15-76 years, with cytological abnormalities and the association
between HPV infection and cervical disease in a subset of 160 women
for whom cytological results for Pap-Test were available, during the
period 2008-2011 in Cagliari (Southern Italy). 
Design and Methods. HPV-DNA extraction was performed by lysis
and digestion with proteinase K and it was typed by using the
INNOLiPA HPV Genotyping Assay.
Results. Overall the HPV prevalence was 52.6%; high-risk genotypes
were found in 68.9% of women and multiple-type infection in 36.1% of
HPV-positive women. The commonest types were HPV-52 (23.4%),
HPV-53 (15.7%), HPV-16 (15.4%) and HPV-6 (12.4%). Among the
women with cytological diagnosis, any-type of HPV DNA was found in
49.4% of the samples and out of these 93.7% were high-risk genotypes.
Genotype HPV 53 was the commonest type among women affected by
ASCUS lesions (21.4%), genotype 52 in positive L-SIL cases (22.5%),
genotype 16 H-SIL (27.3%).
Conclusions. This study confirmed the high prevalence of HPV
infection and high-risk genotypes among women with cervical abnor-
malities while, unlike previously published data, genotype HPV-52 was
the most common type in our series. These data may contribute to
increase the knowledge of HPV epidemiology and designing adequate
vaccination strategies.
Introduction
Genital Human Papillomavirus (HPV) infection is the most frequent
sexually transmitted viral infection all over the world; it is responsible
for clinical forms including both asymptomatic and benign form or
malignant lesions of the cutaneous/mucosal genital tract.1-3 The asso-
ciation of HPV infection with cervical cancer is widely documented.
The majority of cervical cancers are the consequence of persistent
infection by high risk HPV genotypes.4-6 Cervical cancer is the second
most frequent cancer in women worldwide, with 500.000 cases and
250.000 deaths yearly: its frequency is high both in developing and
industrialized areas.7 HPV is associated with other types of cancers
like anal, vaginal, vulva, penis and oropharingeal cancer causing fur-
ther 0.7% of all cancers in women and men; overall, HPV is thus
responsible for 5.2% of cancers worldwide.8-10
At present, more than 140 HPV types have been identified, of which
about 40 infect the genital tract. Fifteen of these have been classified
as high-risk types (HR-HPV) according to the International Agency for
research on Cancer (IARC)11 and 12 are considered as low-risk types
as they are responsible for ano-genital warts and Recurrent
Respiratory Papillomatosis (RRP). The high risk types HPV-16 and
HPV-18 are responsible for approximately 70% of cervical cancers;12-14
worldwide HPV-16 is present in 45% and HPV-18 in 16% of cervical
lesions. Genotypes 31 and 45 account for another 10%.13 
Italian investigations about HPV prevalence in healthy women and in
women with cytological abnormalities reported HPV-16 as the most fre-
quent genotype. However, consistent local differences of other HR geno-
types distribution were observed posing the question about a different
impact of HPV vaccination according to the local prevalent genotypes.15-21
Immunity induced by vaccination to HPV is type-specific. However, if we
consider the phylogenetic tree including the different HPV types, we
realize that a certain degree of cross-protection is possible, due to the
high homology of some viral types with vaccine ones.22,23
The present study reports the frequency of HPV genotypes isolated
in cervical samples of women presenting cytological abnormalities and
attending the cytological screening.
Design and MethodsStudy population 
Cervical scrape specimens were obtained from 650 women [mean
age 37.22 years, standard deviation (SD) 9.3 years, range 15-76 years]
of Cagliari, the main town of Sardinia, an island of Southern Italy, dur-
ing the period 2008-2011. Age class distribution among the recruited
women is reported in Table 1.
Samples were collected from 175 women attending the screening
Significance for public health
Human papillomavirus (HPV) is the most common sexually-transmitted agent,
which can cause cervical lesions and cancer in females. Efforts to reduce the
burden of cervical cancer with cytology screening in the last years have had
limited success. HPV infection and disease imposes a substantial burden of
direct costs on the Italian National Health Service that have never been fully
quantified. Monitoring HPV prevalence could represent a tool to follow the evo-
lution of the infection in the vaccination and post-vaccination era, to under-
stand the impact of HPV types in cervical diseases in Italy. Our survey shows
an high frequency of infections sustained by HPV 52. Given the recent imple-
mentation of a widespread immunization program with vaccines not contain-
ing HPV 52, it has been relevant to prove the high prevalence of this HPV geno-
type from the beginning of the vaccination campaign, to avoid ascribing to the
vaccination program a possible selection effect and the importance of non-vac-
cine HPV types in the burden of cervical disease, in order to assess the oppor-
tunity to realize new vaccine including other types.
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programme at the Prevention Department of the Local Health District,
and from 475 women attending private gynaecologist clinics for the
treatment of cervical lesions. All the specimens were tested for HPV at
the laboratory of Molecular Biology of the University Hospital of
Cagliari but only for a subgroup of 175 women [mean age 38.18, SD
9.04 years; range 20-64 years] a cytological diagnosis was available; the
result of cytological test for the other women was unavailable. The diag-
nosis ware based on the Bethesda system classification: Atypical
Squamous Cells of Undeterminated Significance (ASCUS), Low-grade
Squamous Intraepithelial Lesion (L-SIL) and High-grade Squamous
Intraepithelial Lesion (H-SIL).Extraction of DNA from cervical swab specimens
The cervical swab specimen was collected from each patient using a
cervix brush, suspended in a 20 mL PreservCyt vial (ThinPrep Pap Test
Kit; Cytec Corporation, Malborough, MA, USA) and stored at 4°C until the
DNA extraction. Each vial was vortexed for 15s before the use. Starting
material (1 mL) was centrifugated at 14,000 rpm for 1 min, the super-
natant was removed and the obtained pellet was processed by lysis and
digestion with proteinase K, according to the manufacturer’s protocol
(Blood and Body Fluid Spin Protocol, QIAamp DNA Mini Kit; Qiagen Inc.
Hilden, Germany). The resultant DNA was stored at -20°C until use.Human Papillomavirus-DNA detection and typing
Eluted DNA was used for the PCR amplification of HPV sequences from
the L1 region, using INNO-LiPA HPV Genotyping Extra Amp (Innogenetics
N.V., Gent, Belgium). Particularly the test uses 5’-biotynilated SPF10
primers to amplify a 65 bp fragment within the L1 open reading frame in
HPV genome. An additional primer pair target human HLA-DBP1 gene to
provide a control for sampling and cell adequacy, extraction and amplifi-
cation. PCR was performed in a final reaction volume of 50 L, containing
10 L of the isolated DNA, 10 mM Tris/HCl, pH 9.0, 50 mM KCl, 2.0 mM
MgCl2, 0.1% Triton X-100 0.01% gelatine, 200 M of biotinylated primers in
buffer with dNT/dUTP, 15 pmol of forward and reverse primers each, and
1.5 U of Ampli Taq Gold DNA polymerase (Roche Molecular Systems Inc,
USA). HPV type-specific sequences were detected by the INNO-LiPA
Genotyping Extra (Innogenetics N.V., Gent, Belgium) assay according to
the manufacturer’s instructions: the biotinylated PCR products were
reverse hybridized to genotype-specific probes immobilized as parallel
lines on a nitrocellulose strip. After stringent washing, streptavidin-con-
jugated alkaline phosphatase was added and a non-radioactive reaction
performed using a chromogenic substrate. After drying the strips, the
resulting purple precipitates were visually interpreted according to man-
ufacturer’s protocol by using an interpretation grid supplied with the kit.
The current version of the assay allows the simultaneous and sepa-
rate detection of the following HPV types: HPV-6, 11, 16, 18, 26, 31, 33,
35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69/71, 70, 73, 74
and 82. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and
82 were defined high-risk (HR) HPV types; HPV-26, 53 and 66 were con-
sidered as probable high-risk (pHR), whereas the other genotypes were
defined low-risk (LR) HPVs. HPV amplimers which did not hybridize to
any probe were considered as uncharacterized. Statistical analysis 
Statistical analysis were performed using software SPSS version
18.0. SD was calculated for the mean values. Fisher’s exact test was
used to compare proportions. Trends in proportion were tested using
the Chi-square test for trend. Proportions were computed with the cor-
responding 95% confidence intervals (95% C.I.) according to the
Poisson distribution.
A P value less than 0.05 was considered as statistically significant.
Results
Overall, 342 of the 650 women (52.6%) were positive for any type of
HPV; prevalence according to age classes is reported in Table 1. The
prevalence was significantly higher in women aged 25-35 years than in
the 35-45 and >45 years age classes (P<0.01). 
Of the 342 samples positive for HPV-DNA, 43 (12.6%) could not be
genotyped because they did not match any of the specific probes of the
strips (uncharacterized genotype); thus HPV genotyping was available
for 299 women. Particularly, 206 of the 299 genotyped women (68.9%)
were infected by HR-HPV, 60 (20.1%) by pHR-HPV and 33 (11.0%) by LR-
HPV. The age point prevalence are reported in Table 2: HR-HPV recur-
rence was not significantly different among the age classes (P>0.05). 
Overall, out of 299 infections, 191 (63.9%) were sustained by a sin-
gle genotype and 108 (36.1%) by multiple HPV genotypes; genotypes
distribution in single and multiple infections is shown in Table 3. The
proportion of infections sustained by genotypes 16, 52 and 53 was sig-
nificantly higher than that for all the other genotypes (P<0.05).
Among women with multiple genotypes there were 58 with dual infec-
tion (53.7%), 29 with triple infection (26.8%), 8 women with 4 genotypes
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Table 1. Distribution of age classes among the studied 650
women and positivity prevalence for any type of human papillo-
mavirus (95% confidence intervals).
Age classes (years) No. HPV-DNA positives
No. (%) 95% C.I.
≤24 50 33 (66.0) 52.9-79.1
25-35 244 148 (60.7) 54.5-66.8
36-45 229 104 (45.4) 38.9-51.9
≥46 127 57 (44.9) 36.2-53.5
Total 650 342 (52.6) 48.8-56.5
Table 2. Positivity rates of HR-HPV, pHR-HPV and LR HPV (95% confidence intervals) stratified for age classes in 299 women with
typeable human papillomavirus.
Age classes Tot. HR-HPV positives pHR-HPV positives LR-HPV positives
(years) positives No. (%) 95% C.I No. (%) 95% C.I No. (%) 95% C.I
<24 33 21 (63.6) 39.4-96.9 5 (15.2) 6.1-36.4 7 (21.2) 9.1-42.4
25-35 133 95 (71.4) 57.9-87.2 27 (20.3) 13.5-29.3 11 (8.3) 3.7-15.0
36-45 90 63 (70.0) 53.3-90.0 16 (17.8) 10.0-28.9 11 (12.2) 5.5-22.2
>46 43 27 (62.8) 41.9-90.7 12 (27.9) 13.9-48.8 4 (9.3) 2.3-23.2
Total 299 206 (68.9) 59.9-78.9 60 (20.1) 15.4-25.8 33 (11.0) 7.7-16.1
each (7.4%) and 13 women with 5 or more genotypes each (12%). 
HPV-52 was the most frequent genotype both in single and multiple
infections; overall, it was detected in 70 cases (23.4%), HPV-53 was
detected in 47 (15.7%), HPV-16 in 46 (15.4%), HPV 6 in 37 (12.4%),
HPV-66 in 37 (12.4%) and HPV-51 in 36 (12.0%). HPV-18 was identified
in 18 subjects (6.0% of infections) (Figure 1).
In the subgroup of 175 women for whom a cytological diagnosis
according to the Bethesda system was available, 160 could be geno-
typed (15 were non-typable): 75 (46.9%) were affected by ASCUS
(mean age 39.3 years), 66 (41.2%) by L-SIL (mean age 35.8) and 19
(11.9%) by H-SIL lesions (mean age 37.0). Overall, HPV DNA was found
in 79/160 samples (49.4%, C.I. 95% 41.2-50.0): in 74 infections (93.7%)
HR-HPV or pHR HPV genotypes were detected (Table 4). 
Among women with cytological diagnosis of ASCUS, L-SIL and H-SIL,
28 (37.3%), 40 (60.1%) and 11 (57.9%) respectively were HPV infected.
The frequency of HPV infection was not significantly different in the 3
groups of cytological abnormalities.
Proportions of infections sustained by high risk and probable high
risk HPV genotypes and by low risk genotypes is reported in Figure 2;
the presence of HR HPV was significantly more frequent in women
affected by L-SIL and H-SIL than in ASCUS cases (P<0.05). 
The most frequent isolated HPV genotypes were: genotype 53 in 6 out
of the 28 women affected by an ASCUS lesions (21.4%), genotype 52 in
9 out of the 40 HPV positive L-SIL cases (22.5%), genotype 16 in 3 out
of 11 cases of H-SIL (27.3%). The distribution and proportion of the
HPV genotypes in different classes of cytological abnormalities are
reported in Figure 3. 
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Table 4. Human papillomavirus types in 79 women whit known
cytological diagnosis.
Single Multiple High-risk pHigh-risk Low-risk
infection infections types types types
ASCUS 17 1 11 0 7
L-SIL 29 11 28 10 2
H-SIL 5 6 10 0 1
Total 51 18 49 10 10
Table 3. Human papillomavirus (HPV) genotyping of single or multiple infections in 299 women with detectable HPV DNA.
Genotype Single infection Multiple infection Total number of Proportion
no. (%) no. (%) genotype recurrence (%)
6 25 (13.1) 12 (11.1) 37 12.4
11 0 2 (1.8) 2 0.7
16 21 (10.9) 25 (23.1) 46 15.4
18 12 (6.3) 6 (5.5) 18 6.0
31 1 (0.5) 22 (20.4) 23 7.7
33 0 13 (12.0) 13 4.3
35 1 (0.5) 0 1 0.3
39 9 (4.7) 10 (9.3) 19 6.4
44 4 (2.1) 3 (2.8) 7 2.3
45 1 (0.5) 12 (11.1) 13 4.3
51 18 (9.4) 18 (16.7) 36 12.0
52 33 (17.3) 37 (34.3) 70 23.4
53 24 (12.6) 23 (21.3) 47 15.7
54 2 (1.0) 31 (28.7) 33 11.0
56 6 (3.1) 9 (8.3) 15 5.0
58 2 (1.0) 15 (13.9) 17 5.7
66 23 (12.0) 14 (12.9) 37 12.4
68 1 (0.5) 11 (10.2) 12 4.0
70 2 (1.0) 13 (12.0) 15 5.0
74 6 (3.1) 11 (10.2) 17 5.7
69/71 0 2 (1.8) 2 0.7
Total 191 108 - -
Figure 1. Prevalences of human papillomavirus (HPV) geno-
types, in single or in multiple infections, among 299 HPV geno-
typed samples. 
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Discussion and Conclusions
The distribution of HPV genotypes varies greatly worldwide likely in
relation to the complex geographical and biological interplay between
different HPV types and host immunogenetic factors.24,25
The HPV genotype spreading in the pre-vaccination era was investi-
gated in several European countries.26-28 However, comparison of the dif-
ferent results is problematic as it must consider the characteristics of the
target population, particularly the age of the enrolled women and the
evaluation of women with cervical abnormalities or with normal cervical
cytology; the prevalence rates of HPV infection are expected to be higher
in women with cervical abnormalities considering that HPV is unani-
mously recognized as the main risk factor for cervical lesions.29,30
Furthermore, HPV DNA testing methods are responsible for different
interpretation of results reported in literature, as the different assays
used in surveys have different type-specific sensitivities. In fact,
although the Hybride Capture method (Digeneò HPV Test) is the only
one approved by the Food and Drug Administration (FDA) to evaluate
the presence of high/low-risk oncogenic types, several other technolo-
gies have been used, like Linear Array and standard PCR with different
primers (SPF10, GP05+/GP06+, MY09/11) and real-time PCR. Although
a good concordance has been observed in studies using different diag-
nostical tools, real-time PCR seems to be more sensitive than array
methods to detect positive results.31-33
Our study involved only women with cytological abnormalities of the
cervix who were HPV infected in 52.6% of cases, showing that HPV is
highly endemic in Sardinia. This result is consistent with previous
Italian studies, reporting HPV prevalence ranging from 35.3% to 88.8%
among women with known cervical lesions.18,19,21,27,29,34
The peak of HPV infection was observed in 25-35 years old women
where the prevalence rate was significantly higher than in older
women (60.7% vs 45.4% and 44.9%). This finding is similar with data
reported in other Italian areas, Germany and Denmark,21,26,27,34 reflect-
ing a higher risk in young sexually active women who, however, most-
ly have a transient and asymptomatic infection, with a spontaneous
HPV clearance in 70-90% of cases within 12-13 months.24
In our study a spectrum of 21 genotypes were identified, of which 12
were HR-HPV and 2 pHR-HPV accounting together for 89 % of infec-
tions, in line with rates reported in other Italian studies carried out in
similar populations.18,21,27,29,34
Remarkably, HPV-52 was the most common genotype being present
in 23.4% of all HPV DNA positive women; the high prevalence of this
genotype was reported also in other Italian studies where it was detect-
ed as the second (together with HPV-18),21 the third and the fourth
(together with HPV-51) most frequent genotype in females affected by
H-SIL living in Southern Italy27 or in women with different risk of infec-
tion.35-37 Worldwide HPV-52, together with HPV-16, HPV-18, HPV-31,
HPV-58 is considered one of the five most common types contributing
to the 50% of all HPV infections.27 HPV-52 is considered as the most
common type in Eastern Africa, Japan and Taiwan and the fourth com-
mon type in Eastern Asia27 among women with normal cytology. 
The reason of the high prevalence of HPV-52 observed in our study
might be also explained by the sexual promiscuity among immigrated
women from high risk areas and the local community, likely proving the
active role of men in spreading this infection.30,38
The second most frequent type was HPV-53 (15.7%) in accordance
with other Italian34 and Spanish studies,28,39,40 both in general popula-
tion and in females with abnormal smears. In fact, although it is not
recurrent among the most prevalent types worldwide, it was found as
the second and the fifth,21,30 most frequent genotype isolated in Italian
studies which considered general female population and females with
abnormal smears. The underestimation of the prevalence of HPV-53
infections in many studies may be related to the lack of sensitivity of
the testing methods, particularly those in which amplification with
GP05+\GP06+ primers has been used as screening for HPV positive
samples, while the combination of amplification and hybridization
used in our study for all samples seems to improve its detection.
Another important reason is the absence of the specific probes for HPV-
53 detection when using the Hybride Capture II current high-risk kit.41
Unexpectedly, HPV-16 was detected only in 15.4% of our series, at the
third place in descendent order; however it was predominant among
women affected by H-SIL, confirming that HPV-16 is the most frequent
HPV type associated with high-grade lesions. The lower prevalence of
HPV-16 infection in our cohort compared with the majority of literature
reports could be ascribed to the small proportion of women with
advanced precancerous lesions. Moreover we didn’t include any case of
cervical cancer where HPV-16 is well-known to be predominant.12,13,24,25
Our survey showed that at least 36.1% of women were infected by
two or more genotypes, in accordance with other studies reporting a
prevalence of multiple infections in 30-53% of cases.18,21,42 The clinical
significance of multiple infections remains uncertain; in our cases
they were more frequently found in younger women suggesting a link
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Figure 2. Proportion of positivity to HR/pHR HPV and LR HPV
genotypes according to cytological abnormalities among 160
women for whom a cytological diagnosis according to Bethesda
system classification was available.
ASCUS=Atypical Squamous Cells of Undeterminated Significance.
L-SIL=Low-grade Squamous Intraepithelial Lesion.
H-SIL=High-grade Squamous Intraepithelial Lesion.
Figure 3. Distribution and proportion of the most frequent geno-
types in ASCUS, L-SIL and H-SIL cytological lesions.
with sexual promiscuity. It’s not clear whether multiple infections with
several HPV types increases the progression risk: some reports show
that in immunocompetent women the HPV clearance rate is independ-
ent of the number of genotypes involved in the infection and that mul-
tiple infections are not associated with a greater risk of cervical cancer
compared with single infections.43
Concerning the association between HPV and cytological results,
overall 46.9% of women were HPV infected and 93.7% of them har-
boured HR-HPV genotypes. According to current studies the presence
of HR-HPV was significantly higher in women affected by L-SIL and H-
SIL than in those affected by ASCUS, strengthening the role of persist-
ent infection sustained by HR genotypes in cervical lesions.
The predominance of HPV-53 in ASCUS cases of our observations, is
consonant with the absence of this genotype in advanced cervical
lesions reported in other studies,18,21 while the majority of HPV 52
infection in L-SIL cases is similar to the prevalence reported in anoth-
er Italian study.18,29
In conclusion, the present study investigated about the prevalence of
HPV infection and the HPV genotypes distribution in women with abnor-
mal cytological test living in an area of Southern Sardinia; however, in
our survey the proportion of women affected by high grade cervical
lesions was lower than those of women with low grade or mild lesions.
This situation could explain the relatively low prevalence of HPV-16 and
the predominance of HPV-52. The target of current HPV vaccines, con-
taining HPV-16 and 18 Viral Like Particles, is the prevention of severe
pre-neoplastic cervical lesions and cervical cancer; both these conditions
are strongly correlated with the presence of HPV-16 and also in our series
this genotype was prevalent in high grade lesions. Nevertheless, surveil-
lance programs are aimed to disclose the emergence of local differences
in the prevalence of HPV genotypes not covered by current vaccines and
present in persistent infections, such as HPV-52 in Southern Sardinia.
Thus the assessment of cross-protective properties of HPV vaccines is an
extremely important issue. So far, the cross-protection studies have
shown that the efficacy in prevention of 6-months persistent infection in
HPV naïve women vaccinated with current vaccines does not exceed 30%
against non vaccine genotypes, namely HPV-31, 33, 45, 52, 58.22,23,44-46 It
is clear the need to increase cross immunity studies in order to better
assess the effectiveness of the current HPV vaccines; a better knowledge
about cross protection molecular basis could be useful to formulate a sec-
ond generation of HPV vaccines by including other HPV-types frequently
detected in persistent infections.22,23 
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